ResearchSpace

Pyrimidines in antimalarial drug design

Show simple item record

dc.contributor.author Moleele, SS
dc.contributor.author Gravestock, D
dc.contributor.author Rousseau, AL
dc.contributor.author Van Zyl, RL
dc.date.accessioned 2009-04-20T10:41:01Z
dc.date.available 2009-04-20T10:41:01Z
dc.date.issued 2008-09
dc.identifier.citation Moleele, SS, Gravestock, D, Rousseau, AL and Van Zyl, RL. 2008. Pyrimidines in antimalarial drug designSACI-GDCh Bi-National Organic Chemistry Conference 2008. Incorporating the 10th Frank Warren Conference, Kruger National Park, South Africa, 14-19 September 2008, pp 1 en
dc.identifier.uri http://hdl.handle.net/10204/3321
dc.description SACI-GDCh Bi-National Organic Chemistry Conference '08 Incorporating the 10th Frank Warren Conference, Kruger National Park, South Africa, 14-19 September 2008 en
dc.description.abstract Malaria causes the death of 2-3 million people annually, most of these children under 5 years of age. Approximately 300 million cases of acute malaria are reported each year, 90% of these in Africa. Until recently, folate metabolism has been successfully targeted in both prophylaxis and treatment of malaria. Plasmodium falciparum dihydrofolate reductase-thymidylate synthase (PfDHFR-TS) is a well defined and validated target for malaria chemotherapy. Unfortunately, resistance to the most commonly used anti-DHFR drugs, including pyrimethamine 1 now limits the clinical usefulness of these drugs en
dc.language.iso en en
dc.publisher SACI-GDCh Bi-National Organic Chemistry Conference 2008 en
dc.subject Antimalarial drugs en
dc.subject Pyrimidines en
dc.subject Malaria en
dc.subject Plasmodium falciparum dihydrofolate reductase-thymidylate synthase en
dc.subject PfDHFR-TS en
dc.subject Malaria chemotherapy en
dc.subject Anti-DHFR drugs en
dc.subject SACI-GDCh Bi-National Organic Chemistry Conference 2008 en
dc.title Pyrimidines in antimalarial drug design en
dc.type Conference Presentation en
dc.identifier.apacitation Moleele, S., Gravestock, D., Rousseau, A., & Van Zyl, R. (2008). Pyrimidines in antimalarial drug design. SACI-GDCh Bi-National Organic Chemistry Conference 2008. http://hdl.handle.net/10204/3321 en_ZA
dc.identifier.chicagocitation Moleele, SS, D Gravestock, AL Rousseau, and RL Van Zyl. "Pyrimidines in antimalarial drug design." (2008): http://hdl.handle.net/10204/3321 en_ZA
dc.identifier.vancouvercitation Moleele S, Gravestock D, Rousseau A, Van Zyl R, Pyrimidines in antimalarial drug design; SACI-GDCh Bi-National Organic Chemistry Conference 2008; 2008. http://hdl.handle.net/10204/3321 . en_ZA
dc.identifier.ris TY - Conference Presentation AU - Moleele, SS AU - Gravestock, D AU - Rousseau, AL AU - Van Zyl, RL AB - Malaria causes the death of 2-3 million people annually, most of these children under 5 years of age. Approximately 300 million cases of acute malaria are reported each year, 90% of these in Africa. Until recently, folate metabolism has been successfully targeted in both prophylaxis and treatment of malaria. Plasmodium falciparum dihydrofolate reductase-thymidylate synthase (PfDHFR-TS) is a well defined and validated target for malaria chemotherapy. Unfortunately, resistance to the most commonly used anti-DHFR drugs, including pyrimethamine 1 now limits the clinical usefulness of these drugs DA - 2008-09 DB - ResearchSpace DP - CSIR KW - Antimalarial drugs KW - Pyrimidines KW - Malaria KW - Plasmodium falciparum dihydrofolate reductase-thymidylate synthase KW - PfDHFR-TS KW - Malaria chemotherapy KW - Anti-DHFR drugs KW - SACI-GDCh Bi-National Organic Chemistry Conference 2008 LK - https://researchspace.csir.co.za PY - 2008 T1 - Pyrimidines in antimalarial drug design TI - Pyrimidines in antimalarial drug design UR - http://hdl.handle.net/10204/3321 ER - en_ZA


Files in this item

Thumbnail
Name: Moleele_2008.pdf
Size: 1.504Mb
Format: PDF
View/Open

This item appears in the following Collection(s)

Show simple item record